Tier 1 — highest

The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis

Joanna Popiolek-Kalisz, Emilia Fornal
Current problems in cardiology 2022 47(11):101350

Bibliography

PubMed
PMID 35948195
DOI
10.1016/j.cpcardiol.2022.101350
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignMeta-analysis of randomized blood-pressure trials
ModelHuman evidence synthesis
Sample10 trials; 841 participants
InterventionQuercetin across trial-specific regimens
DurationSearches through May 2022
EndpointsBlood pressure

What the study showed, in plain terms

Published in 2022, this source examined cardiovascular and metabolic health. Its evidence base was 10 trials; 841 participants. It evaluated Quercetin across trial-specific regimens across Searches through May 2022.

Pooled systolic pressure fell modestly, with different subgroup findings for normotensive and hypertensive participants.

Small, heterogeneous, short trials and subgroup dependence limit prediction for an individual patient; clinical event outcomes were not established.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Pooled systolic pressure fell modestly, with different subgroup findings for normotensive and hypertensive participants.
  • The recorded outcome domains were Blood pressure.
  • This synthesis reuses the included study populations; it is not an additional randomized participant cohort.

What this study can and cannot tell us

  • Small, heterogeneous, short trials and subgroup dependence limit prediction for an individual patient; clinical event outcomes were not established.
  • Pooled estimates depend on the included trials and may share participants with companion publications or other reviews. A statistically significant surrogate outcome does not establish disease prevention.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The effects of quercetin supplementation on lipid profiles and inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials
Reza Tabrizi et al. · Critical reviews in food science and nutrition · 2020
Tier 1
Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levels: a systematic review and meta-analysis
Haohai Huang et al. · Nutrition reviews · 2020

Citation network

Articles citing this research paper

3 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology